MedTrace Logo

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

NCT06643208 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2025-06-26

No results posted yet for this study

Summary

This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.

Conditions

  • Intrahepatic Cholangiocarcinoma

Interventions

DRUG

TACE-HAIC, Envafolimab and Lenvatinib

TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib

Sponsors & Collaborators

  • Fujian Provincial Hospital

    lead OTHER

Principal Investigators

  • Maolin Yan, Doctor · Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2027-01-01
Completion
2027-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06643208 on ClinicalTrials.gov